Zodasiran
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Mar 1, 2026 → May 1, 2029
NCT ID
NCT07473843About Zodasiran
Zodasiran is a phase 3 stage product being developed by Arrowhead Pharmaceuticals for Homozygous Familial Hypercholesterolemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07473843. Target conditions include Homozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07473843 | Phase 3 | Recruiting |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia